Reata Pharmaceuticals shares are trading higher after the FDA approved Prior Approval Supplement to update Skyclarys (Omaveloxolone) Drug Substance Specification For Friedreich's Ataxia In adults, adolescents.
Portfolio Pulse from Benzinga Newsdesk
Reata Pharmaceuticals' shares are trading higher following the FDA's approval of a Prior Approval Supplement to update Skyclarys (Omaveloxolone) Drug Substance Specification for Friedreich's Ataxia in adults and adolescents.
June 28, 2023 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reata Pharmaceuticals' stock is trading higher due to the FDA's approval of an update to their Skyclarys drug. This could potentially increase the company's revenues and market share.
The FDA's approval of the update to Reata Pharmaceuticals' Skyclarys drug is a positive development for the company. This could potentially lead to increased sales of the drug, thereby boosting the company's revenues and market share. As a result, the company's stock is trading higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100